Business
business

Eli Lilly tumbles after selling way fewer weight-loss drugs than expected

Shares of Eli Lilly are tumbling after sales of its well-known GLP-1 weight-loss drugs massively undershot Wall Street’s expectations in the fourth quarter.

The company said on Monday that it made approximately $1.9 billion selling Zepbound and $3.5 billion selling Mounjaro in the final quarter of 2024. Analysts polled by FactSet estimated $2.1 billion for Zepbound and $4.4 billion for Mounjaro. 

Both are the same drug (tirzepatide), but Mounjaro is the brand name approved to treat diabetes and Zepbound can be prescribed for a wider range of conditions.

Eli Lilly has struggled to keep up with high demand for its weight-loss drugs. For a chunk of 2024, these drugs were considered in shortage by the US Food and Drug Administration, which allowed copycat compound versions to be sold by companies like Hims & Hers.

“We continued to make progress on our manufacturing build-out, and U.S. supply across all doses of tirzepatide was available throughout Q4,” Eli Lilly CEO David A. Ricks said in a statement. “The rest of our medicines performed within our expectations.”

Ozempic and Wegovy, two other popular GLP-1 weight-loss drugs made by Novo Nordisk, have also faced shortages and have flattened in recent quarters.

Both are the same drug (tirzepatide), but Mounjaro is the brand name approved to treat diabetes and Zepbound can be prescribed for a wider range of conditions.

Eli Lilly has struggled to keep up with high demand for its weight-loss drugs. For a chunk of 2024, these drugs were considered in shortage by the US Food and Drug Administration, which allowed copycat compound versions to be sold by companies like Hims & Hers.

“We continued to make progress on our manufacturing build-out, and U.S. supply across all doses of tirzepatide was available throughout Q4,” Eli Lilly CEO David A. Ricks said in a statement. “The rest of our medicines performed within our expectations.”

Ozempic and Wegovy, two other popular GLP-1 weight-loss drugs made by Novo Nordisk, have also faced shortages and have flattened in recent quarters.

More Business

See all Business
business

Amazon is testing adding GM electric vans to its EV delivery fleet dominated by Rivian

Rivian may have some competition in its electric delivery van division: Bloomberg reports that Amazon is testing a small number of GM’s BrightDrop vans for its fleet.

According to Amazon, the test currently only includes a dozen of the vehicles. Amazon’s fleet also contains EVs from Ford, Stellantis, and Mercedes-Benz.

GM debuted BrightDrop in 2021, but the vehicles have struggled to sell and piled up on GM lots due to high prices and steep competition. GM began offering up to 40% rebates on the vehicles this year.

The test comes as Rivian struggles through tariffs and the end of EV tax credits. Earlier this year, it lowered its annual delivery outlook by about 13%. As of June, Amazon said it has more than 25,000 Rivian vans across the US. Earlier this week, Rivian CEO RJ Scaringe said the company is still on track to deliver 100,000 vans to Amazon by 2030 and is “thinking about what comes beyond” that initial target.

GM has sold 1,592 BrightDrop vans through the first half of the year, more than the full-year total it sold in 2024.

GM debuted BrightDrop in 2021, but the vehicles have struggled to sell and piled up on GM lots due to high prices and steep competition. GM began offering up to 40% rebates on the vehicles this year.

The test comes as Rivian struggles through tariffs and the end of EV tax credits. Earlier this year, it lowered its annual delivery outlook by about 13%. As of June, Amazon said it has more than 25,000 Rivian vans across the US. Earlier this week, Rivian CEO RJ Scaringe said the company is still on track to deliver 100,000 vans to Amazon by 2030 and is “thinking about what comes beyond” that initial target.

GM has sold 1,592 BrightDrop vans through the first half of the year, more than the full-year total it sold in 2024.

business

Paramount Skydance reportedly preparing an Ellison-backed Warner Bros. Discovery takeover bid, sending shares soaring

Paramount Skydance is preparing a majority cash bid for Warner Bros. Discovery, The Wall Street Journal reported, sending shares of both companies surging. The Journal’s sources say the deal is backed by the Ellison family, led by David Ellison.

WBD shares were up 30% on the report, while Paramount Skydance jumped 8%.

The offer would cover WBD’s entire business — cable networks, movie studios, the whole enchilada. That comes after WBD announced plans last year to split into two divisions: one for streaming and studios, the other for its traditional cable and TV assets. A recent Wells Fargo note gave WBD a price target hike, primarily because the analysts viewed it as a prime takeover candidate.

If the deal goes through, it would bring together HBO, CNN, DC Studios, and Warner Bros.’ film library with Paramount+, Nickelodeon, and MTV, all under one umbrella.

The offer would cover WBD’s entire business — cable networks, movie studios, the whole enchilada. That comes after WBD announced plans last year to split into two divisions: one for streaming and studios, the other for its traditional cable and TV assets. A recent Wells Fargo note gave WBD a price target hike, primarily because the analysts viewed it as a prime takeover candidate.

If the deal goes through, it would bring together HBO, CNN, DC Studios, and Warner Bros.’ film library with Paramount+, Nickelodeon, and MTV, all under one umbrella.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.